Shionogi bolsters rare disease portfolio with $2bn IntraBio buyout
Japanese pharma company, Shionogi, is set to acquire IntraBio in a multibillion-dollar deal, adding neurological and movement disorder drug, Aqneursa …
Post
-
-
Lilly deepens ties with Gate Bioscience in $870m deal expansion
Eli Lilly has expanded its partnership and licensing agreement with California-based biotech, Gate Bioscience, to develop molecular gate therapies targeting …
-
Alector shares up after sealing $1.27bn Roche Parkinson’s disease license deal
Roche is paying up to $1.27bn to gain the global rights to Alector’s Parkinson’s disease candidate, giving the drugmaker access …
-
CSL and Alentis ink $1.5bn partnership to progress antifibrotic drug
CSL has penned an exclusive collaboration deal with Swiss biotech, Alentis Therapeutics, which will see the pair join forces to …
-
Pacira partners with Molteni for Exparel commercialisation
Pacira BioSciences has entered into an exclusive agreement with Italian pharmaceutical company Molteni Farmaceutici to distribute and commercialise Exparel across …
-
AstraZeneca opens new R&D centre in Cambridge, US
AstraZeneca has opened a new global strategic research and development (R&D) facility in Massachusetts, US, as part of an investment …
-
Scientists claim Nobel Prize for approach behind light-activated gene therapy
A trio of German and American scientists have won this year’s Nobel Prize in Physiology or Medicine for their discovery …
-
GLP-1RA non-responders: tackling a hidden challenge behind the obesity epidemic
In recent years, the notoriety and uptake of incretin-based therapies such as glucagon-like peptide-1 receptor agonists (GLP-1RAs) has skyrocketed, with …
-
FDA approves expanded indication for Lilly’s Jaypirca
The US Food and Drug Administration (FDA) has approved an expanded indication for Eli Lilly and Company's Jaypirca (pirtobrutinib) as …
-
Bayer plans $2.2bn pharmaceutical manufacturing facility in Ohio, US
Bayer has announced plans to invest $2.2bn in a new pharmaceutical manufacturing facility in Ohio, US. The facility will be constructed …
-
AstraZeneca deepens Summit ties on ADC-bispecific cancer combo testing pact
AstraZeneca and Daiichi Sankyo have partnered with Summit Therapeutics to explore the potential of their co-developed antibody-drug conjugate (ADC), Datroway …
-
Novartis bets on autoimmune BiTEs through $7.8bn Abogen deal
Novartis has become the latest big pharma player to bet on the bispecific T-cell engager (BiTE) modality by inking a …
-
Magazine: Keep it cool
Pharma is being pulled in every direction at once: more complex, more connected, more uncertain. Yet the industry keeps moving, …
-
Drug delivery’s next bottleneck isn’t innovation, it’s industrial capacity
New biologics, expanding indications, and rapid growth in GLP-1 therapies are bringing effective treatments to unprecedented numbers of patients. Yet …
-
Sanofi and Regeneron expand immunology partnership to the tune of $8bn
Having already brought one of the most successful drugs in the world to market, Sanofi and Regeneron are broadening their …
